0H8T Stock Chart & Stats
$5.09
$0.21(4.13%)
At close: 4:00 PM EDT
$5.09
$0.21(4.13%)
Day’s Range― - ―
52-Week Range$1.75 - $6.58
Previous CloseN/A
Volume504.00
Average Volume (3M)7.65K
Market Cap
$911.16M
Enterprise Value$665.37
Total Cash (Recent Filing)$91.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume6,941
30 Day Avg. Volume7,646
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside145.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$5.98M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and positive equity give Aclaris financial flexibility to continue developing its pipeline without substantial interest obligations, although this strength depends on preserving capital while research spending remains high.
Strong Gross ProfitabilityThe high gross margin indicates that existing revenue streams can generate substantial contribution after direct costs. If Aclaris develops recurring collaboration or product revenue, this provides a potentially attractive base for operating leverage.
Flexible Access To CapitalMaintaining an on-demand financing facility improves funding flexibility for clinical development and operations. The company can raise capital when needed without a mandatory commitment, supporting continuity of its research programs.
Bears Say
Severe Revenue ContractionSharp revenue contraction signals limited commercial scale and weak near-term monetization of the business. Continued dependence on collaboration-related income makes funding less predictable and raises the importance of successful pipeline advancement.
Persistent Losses And Cash BurnSustained operating losses and material cash outflows show that Aclaris cannot currently fund research and corporate costs internally. Without meaningful revenue growth, partnering proceeds, or financing, liquidity needs will remain a durable business risk.
Equity Dilution RiskThe ATM facility provides funding access but also creates a clear path to additional share issuance. Repeated equity financing could dilute existing holders and reflects the company’s continuing dependence on external capital to support operations.
Aclaris Therapeutics News
0H8T FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest share price was $1.75 and its highest was $6.58 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $911.16M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 147,198,900 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in GB:0H8T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (145.58% Upside)
$12.50 (145.58% Upside)
Blogger Sentiment
Bearish
GB:0H8T Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.00%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
0H8T Stock 12 Month Forecast
Average Price Target
$12.50
▲(145.58% Upside)